Last reviewed · How we verify
NCT05799716
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
Phase 4 trial testing IVIG in Viremia in 40 participants. Status unknown.
1 April 2024
Quick facts
| Lead sponsor | Shanghai Changzheng Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 40 |
| Start date | 1 April 2023 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 September 2024 |
Drugs / interventions tested
- IVIG — full drug profile →
Conditions studied
- Viremia — all drugs for Viremia →
- Bacteremia — all drugs for Bacteremia →
- Acute Rejection of Renal Transplant — all drugs for Acute Rejection of Renal Transplant →
Sponsor
Shanghai Changzheng Hospital
Who can join
Adults 6 to 65, any sex, with Viremia or Bacteremia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are: 1. How effective IVIG is in preventing donor-derived infections 2. Does IVIG has potential immunomodulatory effect on transplanted organs
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05799716
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IVIG
Trials testing the same drug.
- NCT06064279 — Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC · Phase 1, PHASE2 · withdrawn
- NCT06423989 — Role of Immunoglobulin in Male Infertility · NA · recruiting
- NCT04616001 — IVIG in Patients With Severe COVID-19 Requiring Mechanical Ventilation · Phase 4 · unknown
- NCT04474223 — Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) · Phase 3 · recruiting
- NCT04500067 — Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment · Phase 3 · completed
Other recruiting trials for Viremia
Currently open trials in the same condition.
- NCT06999928 — Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV · NA · recruiting
Other Shanghai Changzheng Hospital trials
Trials by the same sponsor.
- NCT07527884 — The Effect of Radiotherapy After Separation Surgery for Spinal Metastases · NA · not yet recruiting
- NCT07527728 — Postoperative Neurological Recovery and Risk Factor Analysis in Patients With Paralysis Due to Spinal Metastases · not yet recruiting
- NCT07526350 — MTS109 in Patients With Refractory Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07398326 — Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer · Phase 2 · recruiting
- NCT07381257 — Efficacy and Safety of Rifaximin-α in Treating MASLD · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05799716 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Changzheng Hospital
- Last refreshed: 5 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05799716.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing